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Abstract
Introduction: There are almost no studies characterizing the integrative level of blood pressure (BP) regulation.
Materials and methods: 277 people of both genders aged 58.6±6.4 with stage II hypertension disease were random-
ized into six groups. The monotherapy of hypertension disease was conducted in five groups, using nebivolol, lisinopril, 
indapamide, amlodipine, and losartan. The sixth group had a combined therapy (lisinopril/indapamide). The therapy 
effectiveness was assessed at four levels of blood pressure regulation, using the following methods: 1) laser Doppler 
flowmetry, determination of the level of tumor necrosis factor-α and interleukin-10; 2) echocardiography and Doppler 
sonography, ultrasound examination of the renal blood flow, ECG, Holter monitoring of ECG; 3) an examination of the 
heart rate variability level and a quantitative assessment of beta-adrenoreception of erythrocyte cell membranes; 4) the 
regulatory and adaptive status was assessed, using the method of cardio-respiratory synchronism.
Results and discussion: A more significant BP decrease was revealed during a combination therapy (by 20.4% of the base-
line daily value). At the integrative level, an index of the regulatory and adaptive status (iRAS) increased in the treatment 
with lisinopril/indapamide combination (by 40.5%), amlodipine (by 40.5%), losartan (by 35.3%), and lisinopril (by 30.2%). 
Nebivolol administration resulted in a 13.5% decrease in iRAS. Indapamide therapy had no significant effect on iRAS.
Conclusion: A comprehensive assessment of the blood pressure regulation system makes it possible to control the 
effectiveness of the therapy not only on a target organ or function, but also on the condition of the organism as an 
integral system.
Keywords
blood pressure, blood pressure regulation, integration of blood pressure regulation levels, assessment of treatment 
effectiveness for primary hypertension.
Introduction
Previously accumulated data on the mechanisms of blood 
pressure (BP) regulation in human body made it possible 
to shape the concepts of the system to maintain (or to 
stabilize) BP (Coffman 2011, Rahmouni 2016).
It seems that creating a comprehensive evaluation of 
the BP regulation system at 4 levels (this classification is 
proposed to be used basing on the theory of a hierarchical 
system of BP regulation): 1) integrative level; 2) vege-
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tative level (through the autonomic nervous system); 3) 
organ level; and 4) peripheral level (endothelial-microcir-
culatory) will facilitate the development of new methodo-
logical approaches to the understanding of pathogenesis 
of and to the improvement of treating hypertension. 
Currently, the ideas concerning local humoral mecha-
nisms of BP regulation are being successfully developed, 
and the progress in this direction is quite significant (Bur-
nier and Forni 2012, Mangiafico et al. 2013, Markov 2005, 
Ruilope et al. 2010, Wood et al. 2013). The role of kidneys 
and heart in BP maintenance is known and well-researched 
(Carlström et al. 2015, Esler 2015, Qu et al. 2016, Roman 
et al. 2016, Wu et al. 2016). The significance of the tonus 
of sections of autonomic nervous system in BP formation 
is discussed in (Bakris and Nathan 2014, Bhatt et al. 2014, 
Mu et al. 2011). In recent years, the genetic component in 
the regulation of BP has been intensively examined (Ehret 
et al. 2016, Liu et al. 2016, Surendran et al. 2016).
At the same time, there are almost no studies charac-
terizing the integrative level of regulation, uniting the 
above levels into a single system and determining the sta-
te and targeting of a vegetative (autonomic), organ and 
peripheral regulation mechanisms. The reason seems to 
be the absence of methodological approaches providing 
a quantitative assessment of the integrative regulation 
level in hypertension (Pokrovskii and Polischuk 2016). 
This approach is declared in the study (Pokrovskii and 
Kompaniets 2012), which focuses on the inverse relati-
onship between a hypertension degree and a level of re-
gulatory and adaptive status determined by the method 
of cardio-respiratory synchronism. At the same time, the 
integrative level has not been considered in combination 
with other levels of BP regulation yet. 
Objective: this research was conducted for a simulta-
neous comprehensive assessment of abnormalities of BP 
regulation in hypertensive disease at four levels, inclu-
ding the integrative level.
Materials and methods 
A total of 277 people of both genders, aged 45 to 65 
(58.6±6.4 years (M±SD)) with diagnosed hypertension 
stage II, degrees 1 or 2, moderate or high risk, disease du-
ration from 3 to 14 years (7.2±1.4 years) participated in 
the study. The study did not include any people with sig-
nificant comorbidity. Inclusion criteria: diagnosed stage II 
arterial hypertension, 1 or 2 degrees, moderate or high risk.
Exclusion criteria: acute forms of coronary artery di-
sease, cardiac angina, clinically significant arrhythmias 
and conduction disorders, previous or current disorders 
of cerebral circulation (hemorrhagic or ischemic stroke, 
transient ischemic attacks), types 1 and 2 diabetes mel-
litus or abnormalities of carbohydrate tolerance, chronic 
heart failure above functional class I, disorders of uric acid 
metabolism, secondary hypertension forms, obstructive 
respiratory diseases, renal or hepatic insufficiency, con-
comitant diseases of inflammatory nature, allergic, onco-
logical, hematological and mental illnesses, patients who 
had not reached the target BP level and who was taking 
psychotropic or vegetocorrective drugs, and intolerance 
to systemic administration of antihypertensive drugs.
The control group consisted of 56 healthy indivi-
duals (32 men, 24 women) aged 52.3±4.2 with clinical 
BP<140/90 mm Hg. The results of the study in the control 
group were used as a reference range for patients with 
hypertension. All patients gave their written informed 
consent to participate in the study. 
To determine the disorders of BP regulation system 
mechanism at the peripheral level, the following methods 
were used: 
1. Laser Doppler flowmetry (LDF) on a LAKK-01 de-
vice (Lazma Scientific Productive Enterprise Laser 
Medical Devices, Russia). The probe was located in 
the area of the posterior surface of the left forearm 
at the point located 3–4 cm above the base of the 
ulnar and radial styloids along the median line (ten-
der (Head’s) lines). Two hours before the study, the 
patients were forbidden to eat or drink. The patient 
had 15–20 minutes to get used to the new environ-
ment. The initial LDF-gram was recorded when the 
patient was lying on his/her back supine position, 
with the arms along the body, in the absence of ex-
ternal influences. The probe was close to the skin, at 
the same time without compression of surrounding 
tissues, and preventing the probe from moving too 
much. The ambient temperature in the room during 
the measurements varied within 21–24 degrees. The 
LDF-gram recording continued for 15 minutes with 
assessing the following indicators:
Im index of microcirculation (Kozlov et al. 2017);
SD standard deviation of Im;
CV Coefficient of variance (Cv=SD/Im×100%);
NT neurogenic tone (frequency range 0.02–0.052 
Hz, NT=SD×mean BP/(Аn×Im),
Аn maximum oscillation amplitude in the neurogenic 
range; 
MT myogenic tone (frequency range 0.07–0.15Hz, 
МТ=SD×mean BP/(Аm×Im),
Аm maximum oscillation amplitude in the myogenic 
range;
EDTC endothelial activity (endothelial-dependent com-
ponent of the tone) (frequency range 0.0095–0.02 
Hz, EDTC=SD×mean BP/(Аe×Im), 
Аe maximum oscillation amplitude in the endotheli-
al activity range;
CBRF capillary blood flow reserve.
By the results of the conducted tests, evaluating the 
ratio Im at rest and CBRF by occlusive sampling, the fol-
lowing types of microcirculatory bloodstream were dis-
tinguished (Makolkin et al. 2002): 
• normocirculatory (Im – 4–6 perfusion units (PU), 
CBRF – 200–300%);
• hyperemic (Im > 6 PU, CBRF < 200%);
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• spastic (Im < 4.5 PU, CBRF > 300%);
• stagnant (Im < 4.5 PU, CBRF < 200%);
• stasic (Im < 4.5 PU, CBRF < 200%).
2. Determination of proinflammatory cytokine level – 
tumor necrosis factor-α (TNF-α), anti-inflammatory 
cytokine – interleukin-10 (IL-10); and balance of 
pro- and anti-inflammatory cytokines (TNF-α/IL-10 
coefficient).
To determine the disorders of BP regulation system me-
chanisms at the organ level, the following steps were made:
1. B- and M-mode echocardiography and a Dop-
pler sonography on a Vingmed System 5 Doppler 
echocardiographic unit (Israel), with a 3.5-MHz 
transducer, to determine the structural and func-
tional myocardium condition;
2. examination of the renal blood flow with a 
Philips HD-11XE ultrasonic scanner (USA), us-
ing a triplex Doppler sonography with a 2.5–5-
MHz curvilinear transducer and a pulse-wave 
Doppler color mapping; the quantitative analysis 
included the determination of peak systolic ve-
locity (PsV), end diastolic velocity (EDV) with a 
calculation of the resistance index (RI) by formu-
la: RI = (PsV−EDV) / PsV;
3. electrocardiography on a Siemens-Sicard elec-
trocardiograph (Germany), evaluating the Cor-
nell Index, Sokolow-Lyon index and other stan-
dard indicators;
4. Holter monitoring of ECG with help of a Schiller 
MT-100 unit (Switzerland), standard indicators 
were analyzed to identify cardiac arrhythmias 
and conduction disorders.
To determine the disorders of BP system regulation 
mechanism at the vegetative level (through the autonomic 
nervous system), the following methods were used;
1. The examination of the heart rate variability (HRV) 
(Lucini et al. 2014, Polupanov et al. 2014, Sala et 
al. 2017) by a five-minute ECG recording using 
VNS-Micro software (Neurosoft LLC, Russia) with 
the assessment of the following indicators:
• RRNN – average of R-R intervals;
• SDNN – standard deviation of normal to normal 
R-R intervals;
• CV– coefficient of variance of R-R intervals (CV = 
SDNN/RRNN×100%);
• TP (Total Power) – total capacity of HRV spec-
trum;
• LF – average of the low-frequency component of 
HRV spectrum capacity;
• HF – average of the high-frequency component of 
HRV spectrum capacity;
• VLF – average of the very low-frequency compo-
nent of HRV spectrum capacity;
• LF norm – the relative capacity of low-frequency 
waves in normalized units (LF norm = LF/(TP−
VLF)×100%);
• HF – relative capacity of high-frequency waves 
in normalized units (HF norm = HF/(TP−
VLF)×100%);
• VLF – average spectrum capacity of an HRV very 
low frequency component;
• LF% – spectrum capacity of low-frequency vari-
ability component as a percentage of the total oscil-
lations power; 
• HF% – spectrum capacity of high-frequency vari-
ability component, as a percentage of the total os-
cillations power; 
• VLF% – spectrum capacity of very low-frequency 
variability component, as a percentage of the total 
oscillations power; 
• CI – centralization index (predominance of the ac-
tivity of the central regulation circuit over the auto-
nomic one);
• LF/HF – vagosympathetic interaction index 
(Baevskij et al. 2002).
The following vegetative regulation types were distin-
guished: sympathicotonic (LF/HF > 1.05), parasympa-
thetic (LF/HF < 0.95) and mixed (0.95 < LF/HF < 1.05). 
2. A quantitative assessment of beta-adrenoreception 
of erythrocyte cell membranes (β-ARM) by bio-
chemical method (Striuk et al. 2012) (with an en-
hanced activity of the sympathoadrenal system re-
sulting in the circulation of its mediators in blood 
and desensitization of adrenoceptors of red blood 
cell membranes; β-ARM values increasing).
To determine the disorders of BP system regulation 
mechanism at the integrative level, the regulatory and 
adaptive status was assessed using the method of car-
dio-respiratory synchronism.
The sequence of processes through which cardiorespi-
ratory synchronism develops can be represented by some 
stages. The first stage is perception of a signal from the 
stimulus that sets the respiratory rate. The second sta-
ge includes analyzing this signal and setting the task of 
arbitrary control of the respiratory rate. The third stage 
is a conscious formation of the respiratory rate in time 
with the stimulator and irradiation of excitation from the 
respiratory to cardiac center. Then the efferent impulses 
are transmitted along vagus nerves from the medulla 
oblongata to the rhythmogenic structures of the heart. The 
fourth stage is an interaction of these pulses with the pace 
maker. The final result is heart rate generated according 
to the fixed frequency – development of cardiorespiratory 
synchronism. 
A complex of interacting body systems engaged in im-
plementing the phenomenon of cardiac respiratory syn-
chronization makes it possible to use this method for an 
integrative assessment of the condition of the body regu-
latory systems (Pokrovskii and Polischuk 2016).
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The possibility of such an assessment for the BP regu-
lation system is discussed in (Pokrovskii and Kompaniets 
2012). The examination by using the method of cardiores-
piratory synchronism was performed using a software and 
hardware complex, including a VNS-Micro unit providing 
a synchronous recording of ECG and pneumogram, and 
original software for implementing a signal generating al-
gorithm, setting the respiratory rate, recording the onset 
of cardiorespiratory synchronization and its parameters, 
and for calculating the index of regulatory and adaptive 
status (iRAS) by the following formula: 
iRAS = (synchronization range / synchronization peri-
od at the minimum range) × 100 (Pokrovskii and Po-
lischuk 2016).
Along with the level analysis of regulation mecha-
nisms, BP daily monitoring was performed by using an 
MnSDP-2 unit (Russia) to establish a daily BP profile.
The patients with hypertension were randomized into 
groups for a prescribed monotherapy: nebivolol (Nebilet, 
Berlin Chemie, Germany) at a dose of 7.2±2.8 mg/day – 
51 people; lisinopril (Diroton, Gideon Richter, Hungary) 
at a dose of 15.9±4.1 mg/day – 50 people; losartan (Lo-
rista, KRKA, Slovenia) at a dose of 84.5±15.5 mg/day – 
30 people; indapamide (Arifon-retard, Servier, France) at 
a dose of 1.5 mg/day – 45 people; and amlodipine (Normo-
dipine, Gideon Richter, Hungary) at a dose of 8.4±1.6 mg/
day – 44 people. To analyze the sensitivity of the methods 
used to assess the treatment effectiveness at each level of 
BP regulation, the study also included  a more intensive 
therapy group of 57 people treaded with a combination of 
lisinopril and indapamide (at a dose of 8.2±1.8/1.5 mg/
day). The mean values of daily systolic and diastolic BP 
did not vary significantly within the groups. 
The studies by means of all the above-described me-
thods were performed at the beginning and then 1, 3 and 
6 months after the beginning of the therapy. The article 
presents the results of the six-month treatment.
The obtained data were normally distributed. To assess 
the statistical significance of differences in mean values, 
Student’s t-test was used for dependent and independent 
samples, respectively. The differences were regarded as 
statistically significant at p<0.05.
Results and discussion
The positive BP dynamics was observed within the first 
month of the treatment, increased towards the third month 
and remained until the end of the observation period.
The average daily systolic and diastolic BP in the groups 
6 months after starting the treatment were the following: 
when administering nebivolol – 126.6±5.8 and 76.8±5.3 
(M±SD), amlodipine – 129.0±5.1 and 76.1±6.0, losar-
tan – 127.3±4.7 and 75.7±5.4, lisinopril – 125.2±4.5 and 
75.9±5.6, indapamide – 129.3±5.6 and 76.4±6.2, lisinopril/
indapamide − 127.2±5.0 and 76.7±6.1 mm Hg. A more sig-
nificant BP decrease was revealed when using a combination 
therapy (by 20.4% of the baseline daily value). The people 
who had not reached the target BP values within three months 
of observation were excluded from the study. Influenced by 
the antihypertensive therapy (AHT), by month 6 the number 
of patients with “dipper” profile increased, the number of 
patients with a “non-dipper” profile decreased, and a “night 
picker” profile was no longer established (Figure 1). 
Figure 1. The proportion of patients with “dipper” profile and “non-dipper” profile in the groups at the beginning and after 6 months 
of treatment.
Research Results in Pharmacology 5(3): 1–9 5
According to 24-hour BP monitoring data, the ini-
tial regular two-phase BP daily rhythm did not change 
throughout AHT, which suggests a positive physiological 
effect of the drugs prescribed.
The dynamics of all the parameters (with the statistical 
significance of the differences) obtained by using the abo-
vementioned methods at 4 selected levels is presented in 
Tables 1 and 2.
Disorders of BP regulation system mechanisms at the 
peripheral level and their adjustment influenced by an-
tihypertensive therapy
When assessing the peripheral level of BP regulation by 
LDF method in the patients with hypertension before the 
treatment, the following types of microcirculation were re-
vealed: normocirculatory (in 42.3% of patients), spastic (in 
34.4%), and stasic (in 23.3%). The following changes in mi-
crocirculation parameters were observed in the patients with 
hypertension before the treatment in comparison with the 
control group: a decrease in Im (by 14.4%), SD (by 60.2%), 
CV (by 54.3%), MT (by 69.7%); an increase in endothelial 
activity (by 16.6 times); NT values were comparable. 
The increased concentrations of proinflammatory cy-
tokine TNF-α and anti-inflammatory cytokine Interleu-
kin-10 were found in the patients with hypertension in 
comparison with the control group.
Influenced by AHT, by month 6 an increase in propor-
tion of people with normocellular and spastic hemody-
namic microcirculation types was detected; there was a 
decrease in the share of people with the stasic type.
In course of the treatment, a significant decrease in 
TNF-α (11.6%) and IL-10 level (5%) was observed in 
comparison with the baseline data only in the combined 
therapy group (Tables 1, 2).
When administering nebivolol, indapamide, amlodipi-
ne, losartan as well as lisinopril/indapamide combination, 
a significant increase in the SD amplitude of blood flow 
deviations from the arithmetic mean value of microcircu-
lation index was observed.
Besides, when administering  nebivolol, indapamide, 
amlodipine, losartan and the lisinopril/indapamide com-
bination, CV significantly increased. 
In course of the treatment with lisinopril and losartan, 
NT and MT significantly decreased.
Only administering nebivolol and a combination thera-
py (lisinopril/indapamide) led to an increase in the initial-
ly low MT (MT increased by 54% and 118%, respective-
ly). Therapy with nebivolol, indapamide, amlodipine, and 
a lisinopril/indapamide combination significantly decre-
ased the endothelial activity.
Disorders of BP regulation system mechanisms at the 
organ level and their adjustment influenced by antihy-
pertensive therapy
The following types of left ventricular myocardial remo-
deling were revealed in the patients with hypertension: 
concentric hypertrophy (in 86% of patients), and concen-
tric remodeling (in 14%). 
There was a decrease in left ventricular mass index 
(LVMI) (by 7.4% in the treatment with nebivolol and by 
6.9% in the combination therapy) due to the decrease in 
thickness of the posterior wall of the left ventricle and in-
terventricular septum; an increase in the ratio of the early 
(E) to late (A) diastolic transmitral flow velocity (E/A) (in 
treatment with nebivolol by 13.6% and with amlodipine 
− by 9.5%). 
Besides, the following observations were made in all 
the groups: the decrease in thickness of the posterior 
wall of the left ventricle and interventricular septum, a 
decreased final diastolic size of the left ventricle, and a 
decreased isovolumetric relaxation time (IVRT). The size 
of the left atrium did not change significantly. The dif-
ferences between the groups in all these parameters were 
insignificant.
The comparative analysis of the changes in renal blood 
flow showed minor changes influenced by AHT 6 months 
later. 
Disorders of BP regulation system mechanisms at the 
vegetative level (through the autonomic nervous sys-
tem) and their adjustment influenced by antihyperten-
sive therapy
According to the results of HRV examination, the fol-
lowing types of vegetative regulation were revealed in 
patients with hypertension: sympathicotonic – in 49.1% 
of patients, parasympathetic – in 22.4%, and mixed – in 
28.5%. In comparison with the control group, there was a 
decrease in TP (by 34.3%), HF (by 2.0 times), and an in-
crease in VLF% (by 2.5 times), CI (by 3.0 times). β-ARM 
was initially increased in all the patients with hyperten-
sion in comparison with the control group (by 6.8 times).
In the treatment with nebivolol, there was an increase 
in: SDNN – by 39.5%, CV – by 39.2%, TP – by 50.2%, 
and a decrease in: LF/HF (by 48.3%), CI (by 64.4%), and 
β-ARM (by 37.2%).
As a result of the therapy with lisinopril, SDNN in-
creased by 23.8% and TP decreased by 11.5%. At the 
same time, the vagosympathetic interaction index did not 
change significantly, but there was a 45.3%decrease in 
β-ARM.
In the treatment with indapamide and amlodipine, an 
increase was recorded in: TP (by 33.4% and 34.0% for 
indapamide and amlodipine, respectively), LF/HF (by 
21.1% and 22.2%), CI (by 35.6% and 35.7%), β-ARM 
(by 32.1% and 22.6%) (Tables 1, 2).
When administering losartan, SDNN increased by 
24.9%, the vagosympathetic interaction index did not 
change significantly, but there was a 38.5%.decrease in 
β-ARM 
In the combined therapy group, there was an increase 
in SDNN by 44%, CV – by 43.9%, TP – by 50.1% and 
a decrease in CI by 62.2%. LF/HF ratio did not change 
significantly, but β-ARM decreased by 42.9%.
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Drugs used in mono- and combined therapy
lisinopril (n=50) М±SD indapamide (n=45) М±SD lisinopril / indapamide 
(n=55) М±SD
Baseline 6 months Baseline 6 months Baseline 6 months
Periphetral Im, perf.units 4.52±0.81 4.02±0.3§ 4.0±0.5 3.67±0.6§ 3.85±0.5 3.53±0.4§ 4.1±0.6†
SD, perf.units 0.71±0.42 0.25±0.01§ 0.3±0.06 0.32±0.01§ 0.46±0.02† 0.28±0.01§ 0.71±0.04†
Cv % 16.51±7.3 6.2±0.9§ 7.5±0.7 8.7±0.03§ 11.9±0.5† 7.9±0.7§ 17.3±2.6†
NT 0.71±0.2 0.7±0.02 0.48±0.02† 0.73±0.03 0.71±0.02 0.68±0.02 0.68±0.04
МТ 24.4±1.2 8.5±1.1§ 6.8±0.7† 6.13±0.6§ 6.3±0.7 6.8±0.8§ 14.8±1.6†
EDTC 0.45±0.04 6.1±0.8§ 6.2±0.6 8.9±1.3§ 3.7±0.5‡ 8.9±1.4§ 3.7±0.6†
TNF -α, pg/ml 15.9±6.8 18.5±6.4§ 17.8±4.3 18.0±6.5 17.1±5.3 19.0±8.3§ 16.8±5.4†
IL-10, pg/ml 40.8±21.8 42.7±19.0 41.3±22.4 43.0±21.2 42.1±18.2 42.2±17.2 40.1±18.0†
TNF-α /IL-10 0.37±0.3 0.43±0.3 0.41±0.1 0.40±0.5 0.39±0.4 0.45±0.2 0.42±0.1†
Organ LVMI, g/m2 79.2±8.9 126.8±12.4§ 119.8±11.2 121.3±18.2§ 118.1±13.2 126.9±10.6§ 118.1±12.3†
Е/А, units 0.97±0.03 0.88±0.002§ 1.0±0.05 0.82±0.001§ 0.93±0.02 0.84±0.002§ 1.0±0.05
Vegetative 
support
SDNN, ms 34.1±3.3 34.9±3.6 43.2±3.1† 34.8±2.6 35.3±2.9 34.8±3.2 50.1±13.2†
Cv, % 4.0±0.4 4.2±0.1§ 4.6±0.1 3.95±0.02 4.5±0.04 3.96±0.04 5.7±0.01†
TP, mc2 2678.5±21.8 3103.4±48.0§ 2746.3±32.2† 1743.5±35.2§ 2326±36.4† 1744.7±15.2§ 2619.7±26.4†
LF/HF 0.54±0.06 1.2±0.1§ 0.98±0.01 1.9±0.05§ 2.3±0.05† 1.9±0.04§ 0.98±0.04
CI 0.86±0.09 2.2±0.03§ 1.7±0.01 4.5±0.02§ 6.1±0.4† 4.5±0.04§ 1.7±0.04†
β-ARM, cond.units 7.6±0.8 47.5±0.3§ 21.5±0.4‡ 54.2±0.2§ 71.6±0.6† 54.1±4.0§ 23.2±0.5†
Integrative iRAS 75.2±3.4 36.4±0.6§ 47.4±3.4† 39.1±1.5§ 37.1±1.6 29.4±1.2§ 41.3±2.2†
Note: †,‡ − significant changes (in bold) in comparison before and after treatment, p<0.01; <0.001 respectively; § − significant differences from the 
control group, p<0.05; Im − microcirculation rate; SD − standard deviation of Im; Cv − coefficient of variance; NT − neurogenic tone of the micro-
vascular wall; MT − myogenic tone; EDTC − endothelial activity (endothelial-dependent tone component); TNF-α − tumor necrosis factoralpha; 
IL-10 − interleukin-10; HR − heart rate; LVMI − left ventricular mass index; E/A − the ratio of the early (E) to late (A) diastolic transmitral flow 
velocity; SDNN – standard deviation of normal to normal R-R intervals; TP − total spectral power; LF − capacity of low frequency waves; HF − ca-
pacity of high frequency waves; LF/HF − vagosympathetic interaction index; CI − centralization index; β-ARM − β-adrenoreception of erythrocyte 
membranes; iRAS − index of the regulatory and adaptive status.







Drugs used in monotherapy
nebivolol (n=51) М±SD amlodipine (n=44) М±SD losartan (n=30) М±SD
Baseline 6 months Baseline 6 months Baseline 6 months
Periphetral Im, perf.units 4.52±0.81 3.9±0.6§ 3.6±0.4 3.64±0.3§ 3.82±0.2 4.05±0.7§ 4.1±0.2
SD, perf.units 0.71±0.42 0.34±0.02§ 0.46±0.01† 0.30±0.04§ 0.45±0.03† 0.24±0.05§ 0.32±0.04†
Cv % 16.51±7.3 8.7±0.06§ 12.8±0.02† 8.2±0.02§ 11.8±0.3† 5.9±0.6§ 7.8±0.9†
NT 0.71±0.2 0.68±0.01§ 0.63±0.008 0.72±0.01 0.70±0.04 0.71±0.02 0.49±0.05†
МТ 24.4±1.2 7.9±0.8§ 12.2±0.8† 6.15±0.4§ 6.6±0.8 8.3±1.2§ 6.5±0.4†
EDTC 0.45±0.04 7.6±0.5§ 4.6±0.5† 8.7±1.2§ 3.8±0.4‡ 6.0±0.4§ 6.1±0.3
TNF -α, pg/ml 15.9±6.8 17.2±4.1 16.0±5.2 16.9±3.2 15.9±4.0 18.2±5.3 17.4±6.3
IL-10, pg/ml 40.8±21.8 42.1±19.4 41.3±20.5 42.8±17.8 41.4±16.9 43.4±20.1 42.1±22.4
TNF-α / IL-10 0.37±0.3 0.41±0.5 0.40±0.2 0.42±0.3 0.41±0.7 0.39±0.8 0.38±0.6
Organ LVMI, g/m2 79.2±8.9 128.4±7.1§ 118.9±8.6† 122.3±18.0§ 119.0±11.2 118.9±11.2§ 116.0±11.2
Е/А, units 0.97±0.03 0.81±0.02§ 0.92±0.01† 0.84±0.005§ 0.92±0.07† 0.86±0.04§ 0.96±0.03
Vegetative 
support
SDNN, ms 34.1±3.3 32.4±3.0§ 45.2±1.8† 34.6±2.1 34.2±2.2 34.2±3.1 42.7±3.0†
Cv, % 4.0±0.4 3.95±0.07 5.5±0.02† 4.1±0.05 4.3±0.07 4.1±0.1 4.7±0.1
TP, mc2 2678.5±21.8 1743.5±1.9§ 2618.8±9.6† 1739.6±31.8§ 2330.4±31.8† 3101.2±42.3§ 2740.5±30.8
LF/HF 0.54±0.06 1.8±0.5§ 0.93±0.05† 1.8±0.05§ 2.2±0.05† 1.2±0.1§ 0.97±0.01
CI 0.86±0.09 4.5±0.04§ 1.6±0.04† 4.2±0.02§ 5.7±0.4† 2.2±0.03§ 1.5±0.01
β-ARM, cond.units 7.6±0.8 51.9±4.2§ 32.6±0.1† 52.6±0.3§ 64.5±0.1† 50.7±0.8§ 31.2±0.5†
Integrative iRAS 75.2±3.4 37.1±1.6§ 32.1±2.1† 36.8±1.4§ 51.7±2.2† 35.4±0.4§ 47.9±2.3†
Note: †,‡ − significant changes (in bold) in comparison before and after treatment, p<0.01; <0.001 respectively; § − significant differences from the 
control group, p <0.05; Im − microcirculation rate; SD − standard deviation of Im; Cv − coefficient of variance; NT − neurogenic tone of the micro-
vascular wall; MT − myogenic tone; EDTC − endothelial activity (endothelial-dependent tone component); TNF-α − tumor necrosis factor alpha; 
IL-10 − interleukin-10; HR − heart rate; LVMI − left ventricular mass index; E/A − the ratio of the early (E) to late (A) diastolic transmitral flow 
velocity; SDNN – standard deviation of normal to normal R-R intervals; TP − total spectral power; LF − capacity of low frequency waves; HF − ca-
pacity of high frequency waves; LF/HF − vagosympathetic interaction index; CI − centralization index; β-ARM − β-adrenoreception of erythrocyte 
membranes; iRAS − index of the regulatory and adaptive status.
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Disorders of BP regulation system mechanisms at the 
integrative level and their adjustment influenced by 
antihypertensive therapy
The patients with hypertension had a lower level of regu-
latory and adaptive status before the treatment in compa-
rison with the control group (iRAS was by 46.5% lower), 
which is consistent with the previous data (Pokrovskii 
and Kompaniets 2012).
As a result of the six-month therapy against the back-
ground of achieving the target BP values, the integrative in-
dicator iRAS increased in the treatment with the lisinopril/in-
dapamide combination (by 40.5%), amlodipine (by 40.5%), 
losartan (by 35.3%), and lisinopril (by 30.2%). Administra-
tion of nebivolol resulted in an iRAS decrease by 13.5%. 
Indapamide therapy had no significant effect on iRAS. 
The most important task in the treatment of patients 
with hypertension is the achievement of the BP target 
level using five main classes of antihypertensive drugs as 
first-line drugs, but, as shown by the results of meta-anal-
yses of recent years, none of them have an advantage in 
reducing BP (Emdin et al. 2015, Ettehad et al. 2016, Man-
cia et al. 2013, Thomopoulos et al. 2015).
Because of the large amount of earlier data on the ef-
fect of these drugs on BP, this study looked at the other 
parameters that can reflect the condition of BP regulation 
mechanisms at the main levels and proposed the compre-
hensive assessment system described above.
The disorders of BP regulation mechanisms at the 
peripheral level in 57.7% of patients with hypertension 
were represented by pathological types of microcircula-
tion. The increased concentrations of proinflammatory 
cytokine TNF-α and anti-inflammatory cytokine inter-
leukin-10 reflect the immune component of the disease 
pathogenesis (Jastrzebski et al. 2006, Stumpf et al. 2005). 
An increase in the SD of the amplitude of blood flow 
deviations from the arithmetic mean of the microcircula-
tion index characterizes a temporal perfusion variability 
and reflects an increase in the average blood flow modula-
tion within all frequency ranges (Fedorovich 2010) under 
the administration of nebivolol, indapamide, amlodipine, 
losartan as well as lisinopril/indapamide combination. 
The increase in CV when taking nebivolol, indapamide, 
amlodipine, losartan and the lisinopril/indapamide com-
bination reflects the improvement of microcirculation 
condition since it is connected with an increase in SD 
resulting from a more efficient functioning of the active 
mechanisms regulatingtissue blood flow, with practically 
unchanged arithmetic mean of Im.
At the organ level, the results of dynamics analysis of 
morphometric parameters influenced by AHT are consis-
tent with the data from (Borzova and Gorbachenkov 2008), 
describing the changes when taking the drugs included in 
the study. The changes observesd confirm the improve-
ments in structural and functional myocardium condition 
influenced by AHT, especially when taking nebivolol.
At the vegetative level (through the autonomic ner-
vous system), a decrease in the activity of sympathetic 
effects was observed in people taking nebivolol, and an 
increase – in those taking indapamide and amlodipine; 
the therapy with lisinopril, losartan and a combination 
of lisinopril with indapamide did not have a significant 
effect on the type of vegetative regulation of the patients 
according to HRV data, but led to a decrease in β-ARM, 
which approached the normal values in people taking 
lisinopril as a monotherapy, as well as combined with 
indapamide.
At the integrative level, an increase of iRAS in the 
treatment with lisinopril/indapamide combination, am-
lodipine, losartan, and lisinopril reflected the positive 
dynamics, but iRAS values remained lower than in the 
control group. Further prospective studies are needed to 
reveal the mechanisms of regulatory and adaptive status 
recovery in hypertension patients. The open question re-
mains what comes first: deadaptation or hypertension.
The decrease in the level of the regulatory and adap-
tive status during the treatment with a drug from the be-
ta-blocker group (nebivolol) is consistent with the data in 
(Eremina et al. 2016). Bisoprolol, carvedilol, and nebiv-
olol were shown to improve the outcomes in randomized 
controlled trials (RCTs) in heart failure (Ponikowski et 
al. 2016); however, there are no RCTs reporting on the 
outcomes of treating hypertensive patients with these be-
ta-blockers (Williams et al. 2018). According to (Whelton 
et al. 2018), beta blockers are not recommended as first-
line agents unless the patient has ischemic heart disease 
or heart failure.
Due to a high sensitivity of the iRAS used for the de-
scription of the integrative level, it is advisable in further 
studies to assess its potential as an indicator of a risk of 
developing complications. 
Conclusion 
The proposed approach to the complex assessment of BP 
regulation at 4 levels: 1) integrative level; 2) vegetative le-
vel (through the autonomic nervous system); 3) organ le-
vel; and 4) peripheral level (endothelial-microcirculatory) 
makes it possible to analyze the role of each level in the 
primary hypertension development in patients and to mo-
nitor the treatment efficiency. The quantitative evaluation 
of treatment efficiency at the integrative level is a universal 
indicator of a therapy impact based on detecting the effect 
of the treatment not only on a target organ or function, but 
also on the condition of the organism as an integral system.
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